PSMA-positive non-curative metastatic castration-resistant prostate cancer research hub

A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer

This study compares two treatments, Lutetium-177 rhPSMA-10.1 and Pluvicto, for men with advanced prostate cancer that has spread. Researchers want to see which treatment delivers more helpful radiation to the cancer and less to healthy body parts like the kidneys.